Long-term Safety and Effectiveness Study of Fostamatinib for Japanese Patients with Chronic Idiopathic Thrombocytopenic Purpura

What this Trial Is About

This research aims to evaluate the safety and effectiveness of long-term use of fostamatinib in Japanese patients with chronic idiopathic thrombocytopenic purpura ITP. It focuses on understanding how the drug performs under real-world conditions in this patient population. The study is observational, meaning it monitors patients without altering their treatment plans. Participants receive fostamatinib through oral administration as part of their regular care. The study does not assign treatment but observes patients already starting fostamatinib for the first time. There are no separate treatment or placebo groups since this is not an interventional trial. During the study, researchers will collect data on any adverse events over an 18-month period to assess the drugs safety. Participants health and response to the medication will be monitored through routine clinical visits. The total duration of participation aligns with the long-term observation of treatment effects and side effects.

Special Drug Use-results Survey for Long-term Use (Fostamatinib)